Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

Retinitis Pigmentosa Clinical Trial

Official title:

Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03328130
• Other study ID #: HORA-PDE6B-001
• Secondary ID: 2016-001429-16
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 6, 2017
• Est. completion date: December 2029

Study information

• Verified date: March 2024
• Source: eyeDNA Therapeutics
• Contact: Medical Director / Chief Development Officer, MD
• Phone: 01 81 69 87 70
• Email: contact[@]eyednatx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a Phase I/II, monocentric, open-label, dose-ranging safety and efficacy gene therapy intervention by subretinal administration of AAV2/5-hPDE6B.

At least twelve patients 18 years of age or older, within four consecutive cohorts of patients, will be recruited.

Then at least four patients 13 years of age or older, within a fifth cohort, will be recruited.

Description:

Retinitis pigmentosa (RP) is a disease where part of the eye (the retina) is degenerating over time. Patients initially present with night blindness, and later in life experience loss of central vision which leads to blindness. RP is a highly variable disorder with some patients developing symptomatic visual loss in childhood whereas others remain asymptomatic until mid-adulthood. There are no treatments available.

This study focuses on the form of RP caused by mutations (modifications) in the genetic information necessary to make the protein called rod cGMP phosphodiesterase 6 β subunit (or PDE6β). Clinical diagnosis is made by function tests of the eye and confirmed using a specific method called molecular testing to verify that the PDE6B gene is not correct.

This study uses a gene therapy vector inspired from an adeno-associated virus (AAV) called AAV2/5-hPDE6B. This vector intends to supply to the target cells the PDE6B therapeutic gene that is not functioning properly in the cell. The AAV parts of the gene therapy vector work as a vehicle to deliver the normal human PDE6B gene into the cells of the retina.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 23
• Est. completion date: December 2029
• Est. primary completion date: December 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years and older

Eligibility

Key Inclusion Criteria:

• Clinical and molecular diagnosis of retinitis pigmentosa caused by defect in PDE6B gene without other syndromic manifestations

• Aged above 13 years

• Ability to give informed consent

Key Exclusion Criteria:

• Previous ocular surgery or thermal laser within 6 months before the surgery

• Lens opacities or obscured ocular media upon recruitment such reliable evaluation or grading of the posterior segment cannot be performed

• Known serious allergies to the fluorescein dye used in angiography, to the mydriatic, steroidal and non-steroidal eye drops

• Participation in another clinical trial with an investigational agent

• Enrolled or being enrolled in another gene therapy clinical trial

• Active, extraocular infection requiring the prolonged or chronic use of antimicrobial agents

• Chronic medical conditions, cancer

• Abnormal laboratory values

• On immunosuppressive therapy

Related Conditions & MeSH terms

• Retinitis
• Retinitis Pigmentosa

Intervention

Biological:
• AAV2/5-hPDE6B
Subretinal administration in one eye

Locations

Country	Name	City	State
France	Clinique Ophtalmologique, CHU de Nantes	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
eyeDNA Therapeutics

Country where clinical trial is conducted

France, 

References & Publications (2)

Petit L, Lheriteau E, Weber M, Le Meur G, Deschamps JY, Provost N, Mendes-Madeira A, Libeau L, Guihal C, Colle MA, Moullier P, Rolling F. Restoration of vision in the pde6beta-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther. 2012 Nov;2 — View Citation

Pichard V, Provost N, Mendes-Madeira A, Libeau L, Hulin P, Tshilenge KT, Biget M, Ameline B, Deschamps JY, Weber M, Le Meur G, Colle MA, Moullier P, Rolling F. AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6beta-deficient Dogs. Mol Ther. 2016 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of ocular and non-ocular adverse events		1 year + 4 years follow-up
Secondary	Improvement in visual function	Improvement in visual function as assessed by mobility test	1 year + 4 years follow-up
Secondary	Improvement in visual fields	Improvement in visual fields as assessed by visual fields measurements	1 year + 4 years follow-up
Secondary	Improvement in visual function	Improvement in visual function as assessed by reading speed	1 year + 4 years follow-up
Secondary	Improvement in Quality of Life	Quality of life will be measured by Quality of Life questionnaire National Eye Institute Visual Function Questionnaire (NEI VFQ-25)	1 year + 4 years follow-up